Circulating tumor DNA validity and potential uses in metastatic ...

In this article, we will review available evidence supporting the use of ctDNA assays to direct clinical decisions in metastatic breast cancer (mBC).

Circulating tumour DNA testing in metastatic breast cancer - PubMed

ctDNA offers advantages over conventional tissue analyses, as it reflects tumour heterogeneity and enables multiple serial biopsies in a ...

Use of ctDNA in early breast cancer: analytical validity and clinical ...

Circulating free tumor DNA (ctDNA) analysis is gaining popularity in precision oncology, particularly in metastatic breast cancer, ...

Reporting on circulating tumor DNA monitoring in metastatic cancer ...

Circulating tumor-specific DNA (ctDNA) is a group of biomarkers with rapidly increasing interest and the potential to change clinical practice.

Circulating tumor DNA in cancer diagnosis, monitoring, and prognosis

ctDNA has great potential as a blood-based biomarker for the detection and treatment of cancer in its early stages. The purpose of this article ...

Reporting on circulating tumor DNA monitoring in metastatic cancer

The clinical potential in these obser- vations is substantial, but the heterogeneity of the current literature calls for clear definitions and validation of ...

Using Circulating Tumor DNA in Colorectal Cancer: Current and ...

The utility of ctDNA in CRC has broadened from its initial use in the advanced/metastatic setting for molecular profiling and detection of ...

ESMO recommendations on the use of circulating tumour DNA ...

ctDNA has the advantage of being easier to access serially, and provide access to a 'genomic pool' originating from several metastatic sites in the patient. LBs ...

Regulatory implications of ctDNA in immuno-oncology for solid tumors

In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a minimally invasive approach for the diagnosis and ...

Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to ...

Meaning This study suggests that concurrent ctDNA–based and tissue-based genomic profiling identified more patients with targetable, guideline- ...

The interplay of circulating tumor DNA and chromatin modification ...

ctDNA measurements are stable and have the potential to be used in clinical settings. They can be used as a dynamic biomarker of cancer for ...

Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers

ctDNA could potentially be used to monitor the response to adjuvant chemotherapy and metastatic therapy in patients with HER2-positive ...

Circulating tumor DNA in advanced solid tumors: Clinical relevance ...

Metastatic CRC was the first disease in which liquid biopsy was used to study mechanisms of acquired resistance to systemic therapy. In 2012, 2 ...

Personalized Detection of Circulating Tumor DNA Antedates Breast ...

In breast cancer, previous studies have shown the potential utility of ctDNA to detect preclinical metastases and predict relapse following ...

Circulating Tumor DNA Analysis in Patients With Cancer - Allen Press

As noted, there are several contexts in which a ctDNA assay might be applied. We principally focus on the use of ctDNA assays in metastatic ...

Clinical Validity of Tumor-Informed Circulating Tumor DNA...

This ctDNA reflects the presence of tumor cells and may be used to monitor disease progression and treatment response. 8 , 9 As ctDNA comprises only a small ...

Circulating tumor DNA validity and potential uses in metastatic ...

In studies on metastatic breast cancer, ctDNA has been utilized for treatment tailoring, tracking mechanisms of drug resistance, and for predicting disease ...

Unraveling the potential clinical utility of circulating tumor DNA ...

At post-OP, ctDNA detection was lowest for patients later diagnosed with peritoneal (20%) or lung metastases (19%), and highest for metastases ...

Circulating Tumor DNA as a Biomarker for Monitoring Patients with ...

Compared with protein biomarkers, ctDNA provides greater cancer specificity and sensitivity for detecting early recurrent/metastatic disease.

Circulating Tumor DNA Abundance and Potential Utility in De Novo ...

Combined ctDNA and tissue analysis identified potential driver alterations in 94% of patients, whereas ctDNA or prostate biopsy alone was insufficient in 19 ...